News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
262,728 Results
Type
Article (14006)
Company Profile (304)
Press Release (248418)
Section
Business (79396)
Career Advice (152)
Deals (13205)
Drug Delivery (34)
Drug Development (50355)
Employer Resources (31)
FDA (5691)
Job Trends (5121)
News (144201)
Policy (10020)
Tag
Academia (901)
Alliances (21574)
Alzheimer's disease (777)
Antibody-drug conjugate (ADC) (63)
Approvals (5674)
Artificial intelligence (80)
Bankruptcy (99)
Best Places to Work (4537)
Biotechnology (249)
Breast cancer (118)
Cancer (978)
Cardiovascular disease (82)
Career advice (132)
CAR-T (81)
Cell therapy (237)
Clinical research (40316)
Collaboration (364)
Compensation (150)
COVID-19 (1011)
C-suite (95)
Cystic fibrosis (69)
Data (1040)
Diabetes (92)
Diagnostics (1211)
Earnings (29045)
Events (47366)
Executive appointments (294)
FDA (6105)
Funding (356)
Gene editing (69)
Gene therapy (179)
GLP-1 (323)
Government (1066)
Healthcare (6557)
Infectious disease (1051)
Inflammatory bowel disease (99)
IPO (7210)
Job creations (859)
Job search strategy (127)
Layoffs (191)
Legal (1376)
Lung cancer (143)
Lymphoma (63)
Manufacturing (91)
Medical device (2567)
Medtech (2568)
Mergers & acquisitions (6166)
Metabolic disorders (282)
Neuroscience (1050)
NextGen: Class of 2025 (2013)
Non-profit (850)
Northern California (1192)
Obesity (153)
Opinion (92)
Parkinson's disease (82)
Patents (66)
People (25208)
Phase I (14223)
Phase II (18744)
Phase III (11866)
Pipeline (441)
Postmarket research (851)
Preclinical (5977)
Radiopharmaceuticals (207)
Rare diseases (218)
Real estate (1411)
Regulatory (8333)
Research institute (932)
Series A (70)
Southern California (1067)
Startups (1967)
United States (9406)
Vaccines (170)
Weight loss (91)
Date
Today (78)
Last 7 days (507)
Last 30 days (1292)
Last 365 days (20472)
2025 (868)
2024 (20574)
2023 (22415)
2022 (26824)
2021 (27812)
2020 (23359)
2019 (16225)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7428)
Location
Africa (146)
Asia (16995)
Australia (2868)
California (2703)
Canada (858)
China (239)
Colorado (101)
Connecticut (116)
Europe (36574)
Florida (300)
Georgia (76)
Illinois (169)
Indiana (66)
Maryland (361)
Massachusetts (2149)
Minnesota (110)
New Jersey (668)
New York (743)
North Carolina (441)
Northern California (1192)
Ohio (86)
Pennsylvania (515)
South America (207)
Southern California (1067)
Texas (301)
Washington State (264)
262,728 Results for "silverback therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
ARS Pharmaceuticals Closes Merger with Silverback Therapeutics
ARS Pharmaceuticals, Inc. announced the closing of its merger with Silverback Therapeutics, Inc.
November 8, 2022
·
7 min read
Deals
Silverback Therapeutics and ARS Pharmaceuticals Announce Merger
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”) and ARS Pharmaceuticals, Inc. (“ARS”) today announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction
July 21, 2022
·
12 min read
BioForest
Silverback Therapeutics to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright 24th Global Investment Conference from May 23-25, 2022.
May 17, 2022
·
1 min read
BioForest
Silverback Therapeutics to Present at the 42nd Annual Cowen Healthcare Conference
Silverback Therapeutics, Inc. announced that members of the Silverback management team will participate in the 42nd Annual Cowen Healthcare Conference from March 7-9, 2022.
February 24, 2022
·
1 min read
BioForest
Silverback Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), today announced that Silverback management will participate in the SVB Leerink 11th Annual Global Healthcare Conference.
February 3, 2022
·
1 min read
BioForest
Silverback Therapeutics to Participate in the H.C. Wainwright Bioconnect Conference
Silverback Therapeutics, Inc. announced that Silverback management will participate in the H.C. Wainwright Bioconnect Conference from January 10-13, 2022.
January 5, 2022
·
1 min read
Business
Silverback Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update
Silverback Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a business update.
May 12, 2022
·
8 min read
BioForest
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis
Silverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy ® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxis.
October 21, 2022
·
8 min read
BioForest
Silverback Therapeutics Presents Preclinical Data for SBT8230 at AASLD The Liver Meeting 2021
Silverback Therapeutics, Inc. today announced the presentation of preclinical data for SBT8230 at the American Association for the Study of Liver Diseases
November 12, 2021
·
4 min read
Business
Silverback Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Silverback Therapeutics, Inc. today reported financial results for the third quarter ended September 30, 2021, and provided a business update.
November 10, 2021
·
9 min read
1 of 26,273
Next
